Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

The commenter, likely a veterinary professional or clinic owner, argues that the proposed regulation imposes significant financial and operational burdens on veterinary practices and compounding pharmacies. They contend that the requirements lack a clear congressional mandate and will restrict clinical judgment and access to essential medications for patients.

A patient is expressing extreme frustration and requesting that the FDA rescind the decision to place certain peptides on the "category 2 list." The commenter argues that this action prevents compounding pharmacies from providing life-changing therapies to patients.

Antoinette MacAulay and Jamey Sawallisch are private individuals expressing frustration over the FDA's decision to include certain peptides on the Category 2 list. They argue that this action restricts access to life-changing therapies and request that the FDA rescind the list.

A patient is expressing extreme frustration and requesting that the FDA rescind the decision to place certain peptides on the "category 2 list." The commenter argues that this action prohibits compounding pharmacies from providing life-changing therapies to patients.

A private patient is expressing extreme frustration and opposition to the FDA's decision to include certain peptides on the "category 2 list." They argue that these peptides are life-changing therapies and request that the FDA rescind the list to allow compounding pharmacies to continue making them available.

A patient is expressing extreme frustration and requesting that the FDA rescind the decision to place certain peptides on the "category 2 list." The commenter argues that this action prevents compounding pharmacies from providing life-changing therapies to patients.

An individual patient is expressing extreme frustration and requesting that the FDA rescind its decision to place certain peptides on the "category 2 list." The commenter argues that this action prevents compounding pharmacies from providing life-changing therapies for conditions like herniated discs.

A patient is expressing extreme frustration and requesting that the FDA rescind the "category 2 list" for certain peptides. They argue that the decision prevents compounding pharmacies from providing life-changing therapies to patients.

A clinic representative (commenting as an individual) opposes the FDA's decision to move specific peptides to Category 2 of the Bulk Drug Evaluation list. They argue that this move restricts access to beneficial medications for their patients and request that the FDA reconsider the decision based on the compounds' safety and health benefits.